Moleculin Biotech IncMBRX
▼ NegativeCapitalrelevance
Q2 GAAP EPS miss of $1.40 vs expected $0.87, with cash runway into Q1 2027.
Impact on stocks 1
Biotech & Genomic Medicine
Moleculin Biotech IncMoleculin Biotech reported a second-quarter GAAP loss of $1.40 per share, missing expectations by $0.53. As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as of June 30, 2026, together with $9.3 million in financing proceeds raised subsequent to the quarter, will support planned operations into the first quarter of 2027.
Moleculin Biotech IncQ2 GAAP EPS miss of $1.40 vs expected $0.87, with cash runway into Q1 2027.